Yang Y - Search Results

1

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. Among authors: yang y. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.

2

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR; All ZUMA-7 Investigators and Contributing Kite Members. Locke FL, et al. Among authors: yang y. N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11. N Engl J Med. 2022. PMID: 34891224 Clinical Trial.

3

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, Munshi PN, Casulo C, Maloney DG, de Vos S, Reshef R, Leslie LA, Yakoub-Agha I, Oluwole OO, Fung HCH, Rosenblatt J, Rossi JM, Goyal L, Plaks V, Yang Y, Vezan R, Avanzi MP, Neelapu SS. Jacobson CA, et al. Among authors: yang y. Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8. Lancet Oncol. 2022. PMID: 34895487 Clinical Trial.

4

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA. O'Reilly EM, et al. Among authors: yang y. JAMA Oncol. 2019 Oct 1;5(10):1431-1438. doi: 10.1001/jamaoncol.2019.1588. JAMA Oncol. 2019. PMID: 31318392 Free PMC article.

5

Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Yang Y, Wang J, Wang W, Zhang T, Zhao J, Wang Y, Li Y, Wang L, Bi N. Yang Y, et al. Front Oncol. 2022 Jan 28;12:810580. doi: 10.3389/fonc.2022.810580. eCollection 2022. Front Oncol. 2022. PMID: 35155246 Free PMC article.

6

Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy.

Wang Y, Wang W, Zhang T, Yang Y, Wang J, Li C, Xu X, Wu Y, Jiang Y, Duan J, Wang L, Bi N. Wang Y, et al. Among authors: yang y. J Natl Cancer Cent. 2024 Apr 10;4(2):177-187. doi: 10.1016/j.jncc.2024.01.008. eCollection 2024 Jun. J Natl Cancer Cent. 2024. PMID: 39282582 Free PMC article.

7

Longitudinal circulating tumour DNA dynamics predict failure patterns and efficacy of consolidation immunotherapy after chemoradiotherapy in locally advanced non-small-cell lung cancer.

Wang Y, Zhang T, Yang Y, Wang J, Li C, Xu X, Wu Y, Jiang Y, Duan J, Wang L, Bi N. Wang Y, et al. Among authors: yang y. Clin Transl Med. 2024 Mar;14(3):e1619. doi: 10.1002/ctm2.1619. Clin Transl Med. 2024. PMID: 38450838 Free PMC article. No abstract available.

8

Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model.

Wu Y, Li C, Yang Y, Zhang T, Wang J, Tang W, Li N, Bao H, Wang X, Bi N. Wu Y, et al. Among authors: yang y. Cancer Med. 2024 Oct;13(20):e70316. doi: 10.1002/cam4.70316. Cancer Med. 2024. PMID: 39445439 Free PMC article.

9

Tracheoesophageal fistula associated with bevacizumab after thoracic radiotherapy in non-small cell lung cancer: A case report.

Zhang T, Yang Y, Cheng G, Chen P, Bi N. Zhang T, et al. Among authors: yang y. Medicine (Baltimore). 2020 Apr;99(17):e19878. doi: 10.1097/MD.0000000000019878. Medicine (Baltimore). 2020. PMID: 32332657 Free PMC article.

10

Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.

Yang Y, Wang J, Zhang T, Zhou Z, Wang Y, Jiang Y, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Wang W, Xue Q, Wang J, Li YX, Bi N. Yang Y, et al. Front Immunol. 2023 Nov 24;14:1281888. doi: 10.3389/fimmu.2023.1281888. eCollection 2023. Front Immunol. 2023. PMID: 38077319 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108,691 results

Search Page

Filters